ACTRN12622000258752尚未招募2 期
Phase IIa double blind randomized controlled trial of Type 1 Interferon (IFN -1)/ Hyaluronic Acid formulation for the early treatment of SARS-CoV2 infection (COVID-19)
IntraVital0 个研究点目标入组 100 人开始时间: 2022年2月11日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.Males or females, aged greater than or equal to 18 years
- •2.Body mass index (BMI) less than or equal to 40.0 kg/m2 and greater than 15kg/m2
- •3.Diagnosis of SARS-CoV2 infection by PCR of nasopharyngeal swab, conducted by a NATA accredited laboratory (or international GLP equivalent) within the past 48hrs
- •4.enrolment within 96 hours from symptom onset (symptoms include: runny nose, headache, sore throat, fever or cough)
- •5.Willing and able to provide informed consent and comply with all study procedures and restrictions and the required visit schedule
- •6.Total Nasal Symptom Score at baseline less than 5
排除标准
- •1.Age < 18 years old
- •2.Concurrent enrolment in other COVID-19 trials involving investigational agents administered within the last 30 days
- •3.Symptoms of pre-existing or intercurrent respiratory tract illness or infection such as pneumonia, bacterial or fungal sinusitis
- •4.Recent sinus surgery (last 2 weeks)
- •5.Suspected or confirmed convalescent COVID-19, defined as any previous positive test in the prior 4 weeks before the most recent positive test
- •6.Inability to operate a nasal spray device
- •7.Inability to provide verbal consent and written consent via eREDCAP
- •8.Known sensitivity/allergy to interferon
- •9.Current use of interferon for another indication
- •10.Major comorbidities increasing risk of study drug including i. Hematologic malignancy, ii. Advanced (stage 4-5) chronic kidney disease or dialysis therapy (eGFR< 29 ml/min), iii. Known history of ventricular arrhythmias iv. Current use of drugs that prolong the QT interval
- •11.Presence or history of substance abuse, including but not limited to cocaine, opioids and marijuana
- •12.Current use of systemic immunosuppressive therapy that cannot be suspended for duration of trial
- •13.Psychiatric disorders that are considered by the treating clinician to be a contraindication to interferon therapy. [i.e., those with mild or well-controlled psychiatric disorders (e.g., mild depression) may be included]
- •14.Any infection requiring IV antibiotics within 4 weeks of Screening, or oral antibiotics within 2 weeks of Screening.
- •15.Females who are pregnant, lactating, or who have a positive pregnancy test.
- •The effects of Gelferon on the unborn child and on the newborn baby are not known. Because of this, participants must not participate in the research if pregnant, trying to become pregnant, breastfeeding, or planning ovum donation.
- •16.Known or suspected hypersensitivity or contraindication to any of the ingredients in the study drug
- •17.Any condition that in the opinion of investigator is a contraindication to the study
- •18.Regular use of topical nasal spray or nasal douching
研究者
相似试验
进行中（未招募）
1 期
PPALM - Palm oil and Pentoxifylline Against Late MorbidityAdverse effects of radiotherapy for pelvic cancer.EUCTR2012-004211-31-GBThe Royal Marsden NHS Foundation Trust62
进行中（未招募）
2 期
Sotagliflozin in patients with heart failure symptoms and type 1 diabetesType 1 Diabetes, Heart FailureNutritional, Metabolic, EndocrineISRCTN79322795niversity of Dundee320
招募中
2 期
Phase 2 study of oral semaglutide tablet for patients with Parkinson's diseaseD010300Parkinson's diseaseJPRN-jRCT2051230090Kimura Yasuyoshi99
已完成
2 期
The double-blind, randomised controlled phase II study of the adjuvant therapy using alpha-galactosylceramide pulsed antigen presenting cells for patients with head and neck mucosal melanoma followed by a carbon ion radiotherapy.JPRN-UMIN000009430Department of Otorhinolaryngology, Graduate School of Medicine, Chiba University50
已完成
2 期
The double-blind, randomised controlled phase II study of the adjuvant therapy using alpha-galactosylceramide pulsed antigen presenting cells for patients with head and neck mucosal melanoma followed by standard therapy.Head and neck squamous cell carcinomaJPRN-UMIN000009607Chiba University Hospital66